(AXGN) Axogen - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US05463X1063

AXGN: Grafts, Connectors, Protectors, Caps, Tools, Implants

Axogen Inc. stands at the forefront of peripheral nerve regeneration, offering a comprehensive suite of innovative solutions designed to transform traditional repair methods. Their flagship product, Avance Nerve Graft, is a revolutionary off-the-shelf allograft that eliminates the need for a second surgery, thereby reducing patient recovery time and complications. Complementing this are the AxoGuard products, which utilize porcine submucosa extracellular matrix (ECM) to create biological scaffolds that promote tissue repair without immune rejection risks. These include AxoGuard Nerve Connector for tensionless repairs, Nerve Protector for wrapping and reinforcing damaged nerves, HA+ Nerve Protector with a hyaluronate-alginate gel coating for enhanced protection, and Nerve Cap to prevent neuroma formation. Additionally, AxoTouch aids in assessing nerve regeneration through skin innervation measurement. Targeting a niche yet critical market, Axogens products are sought by reconstructive surgeons, orthopedic specialists, and oral surgeons, underscoring their role in advancing patient care.

Looking ahead, Axogens future prospects are intriguing. With a market cap of $792.15M, the companys high P/B ratio of 7.96 reflects market confidence in its asset value and growth potential. Despite a negative RoE, indicative of strategic investments in innovation and market expansion, the forward P/E of 50 signals anticipation of substantial growth. As the demand for effective nerve repair solutions rises, Axogens valuation may be justified by its ability to maintain its leadership position and expand its product portfolio. The companys focus on research and development, coupled with its strong market position, positions it as a compelling player in the medical technology sector, poised for continued growth and innovation.

Additional Sources for AXGN Stock

AXGN Stock Overview

Market Cap in USD 786m
Sector Healthcare
Industry Medical Devices
GiC Sub-Industry Health Care Equipment
IPO / Inception 1990-03-27

AXGN Stock Ratings

Growth 5y 34.1%
Fundamental 9.34%
Dividend 0.30%
Rel. Strength Industry 114
Analysts 4.67/5
Fair Price Momentum 17.99 USD
Fair Price DCF 0.67 USD

AXGN Dividends

Dividend Yield 12m 0.00%
Yield on Cost 5y %
Annual Growth 5y 0.00%
Payout Consistency 1.0%

AXGN Growth Ratios

Growth Correlation 3m 57.6%
Growth Correlation 12m 92.7%
Growth Correlation 5y -29.9%
CAGR 5y 14.78%
CAGR/Max DD 5y 0.17
Sharpe Ratio 12m 0.55
Alpha 107.41
Beta 0.39
Volatility 53.78%
Current Volume 377.7k
Average Volume 20d 601.9k
What is the price of AXGN stocks?
As of March 14, 2025, the stock is trading at USD 17.16 with a total of 377,729 shares traded.
Over the past week, the price has changed by -3.43%, over one month by -5.40%, over three months by +21.19% and over the past year by +113.17%.
Is Axogen a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Axogen is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 9.34 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AXGN as of March 2025 is 17.99. This means that AXGN is currently overvalued and has a potential downside of 4.84%.
Is AXGN a buy, sell or hold?
Axogen has received a consensus analysts rating of 4.67. Therefor, it is recommend to buy AXGN.
  • Strong Buy: 4
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
What are the forecast for AXGN stock price target?
According to ValueRays Forecast Model, AXGN Axogen will be worth about 19.7 in March 2026. The stock is currently trading at 17.16. This means that the stock has a potential upside of +14.57%.
Issuer Forecast Upside
Wallstreet Target Price 25 45.7%
Analysts Target Price 18.5 7.8%
ValueRay Target Price 19.7 14.6%